1. Scrip
  2. >>R&D

Abbott’s Cloherty On Viral Surveillance And Evolving Viruses

 
• By Anju Ghangurde

Gavin Cloherty, Abbott’s head of infectious disease research, tells Scrip how the company’s global viral surveillance program helps it stay ahead of HIV and hepatitis evolution, outlines efforts at a partnership in India on viral diversity to help improve diagnostic accuracy and shares new findings from the company’s virus discovery program.

Cloherty_Gavin
Dr Gavin Cloherty, Head of Infectious Disease Research, Abbott • Source: Abbott

India joined Abbott Laboratories Inc.’s global viral surveillance efforts last year and Gavin Cloherty, the US company’s head of infectious disease research, highlighted how things are shaping in its alliance in the area with YRG CARE, a leading institution for HIV/AIDS research in India.

YRG Care was founded by the late Dr Suniti Solomon, who documented the first cases of HIV infection in the country and is recognized for her pioneering efforts in the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 
• By Jessica Merrill

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

More from Scrip

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

Quotables: Pharma Leaders On The Month’s Hot Topics

 
• By Anabel Costa-Ferreira

The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.